Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer by Deitelzweig, Steve et al.
City University of New York (CUNY) 
CUNY Academic Works 
Publications and Research New York City College of Technology 
2021 
Effectiveness and Safety of Oral Anticoagulants Among 
Nonvalvular Atrial Fibrillation Patients With Active Cancer 
Steve Deitelzweig 
Ochsner Clinic Foundation 
Allison V. Keshishian 
CUNY New York City College of Technology 
Yan Zhang 
Bristol Myers Squibb 
Amiee Kang 
Bristol-Myers Squibb 
Amol D. Dhamane 
Bristol-Myers Squibb 
See next page for additional authors 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/ny_pubs/778 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Authors 
Steve Deitelzweig, Allison V. Keshishian, Yan Zhang, Amiee Kang, Amol D. Dhamane, Xuemei Luo, 
Christian Klem, Mauricio Ferri, Jenny Jiang, Huseyin Yuce, and Gregory Y.H. Lip 
This article is available at CUNY Academic Works: https://academicworks.cuny.edu/ny_pubs/778 
ORIGINAL RESEARCH
Effectiveness and Safety of Oral
Anticoagulants Among Nonvalvular Atrial
Fibrillation Patients With Active Cancer
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Amol D. Dhamane, MS,e Xuemei Luo, PHD,f Christian Klem, PHARMD,e Mauricio Ferri, MD,e Jenny Jiang, MS,e
Huseyin Yuce, PHD,d Gregory Y.H. Lip, MDg,h
ABSTRACT
BACKGROUND Patients with cancer are more likely to develop nonvalvular atrial fibrillation (NVAF). Currently there
are no definitive clinical trials or treatment guidelines for NVAF patients with concurrent cancer.
OBJECTIVES This subgroup analysis of the ARISTOPHANES study compared the risk of stroke/systemic embolism
(stroke/SE) and major bleeding (MB) among NVAF patients with active cancer who were prescribed non–vitamin K
antagonist oral anticoagulants (NOACs) or warfarin.
METHODS A retrospective observational study was conducted in NVAF patients with active cancer who newly initiated
apixaban, dabigatran, rivaroxaban, or warfarin from January 1, 2013, through September 30, 2015, with the use of
Medicare and 4 U.S. commercial claims databases. Cox models were used to estimate the risk of stroke/SE and MB in the
pooled propensity score–matched cohorts.
RESULTS A total of 40,271 patients were included, with main cancer types of prostate (29%), female breast (17%),
genitourinary (14%), and lung (13%). Compared with warfarin, apixaban was associated with a lower risk of stroke/SE
(hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.45-0.78) and MB (HR: 0.58; 95% CI: 0.50-0.68); dabigatran
and rivaroxaban had similar risks of stroke/SE (dabigatran: HR: 0.88 [95% CI: 0.54-1.41]; rivaroxaban: HR: 0.82 [95% CI:
0.62-1.08]) and MB (dabigatran: HR: 0.76 [95% CI: 0.57-1.01]; rivaroxaban: HR: 0.95 [95% CI: 0.85-1.06]). Risks of
stroke/SE and MB varied among NOAC-NOAC comparisons, while consistent treatment effects were seen for all treat-
ment comparisons across key cancer types.
CONCLUSIONS Among this cohort of NVAF patients with active cancer, the risk of stroke/SE and MB varied among
oral anticoagulants and were consistent across cancer types. (J Am Coll Cardiol CardioOnc 2021;3:411–424) © 2021
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A trial fibrillation (AF) is a heartrhythm condition that may lead tosubstantial morbidity and mortality,
specifically in aging populations (1). In the
U.S., 2.3 million individuals are considered
to have AF, with an expected increase to 5.6
million by 2050 (1,2). AF occurs with many
coexisting health conditions, including hy-
pertension, coronary heart disease, chronic
kidney disease, and diabetes mellitus (3). In
addition, there is accumulated evidence sug-
gesting an association between the incidence
of AF and cancer (4,5).
A recent systematic review and meta-
analysis of the association between cancer
and AF revealed that patients with solid can-
cer were at a higher risk of developing AF
comparedwith noncancer patients (4). Similarly, in the
REGARDS (Reasons for Geographic and Racial Differ-
ences in Stroke Study), cancer patients were more
likely to have prevalent AF than those without cancer
(5). In addition, gastric, ovarian and cervical cancer
patients have been associated with a higher risk of
ischemic stroke compared to non-cancer patients (6-
8), and it has been reported that major bleeding (MB)
occurs in w10% of all cancer patients (9).
Traditionally AF has been managed with the use of
oral anticoagulants (OACs), such as vitamin K antago-
nists, but non–vitamin K antagonist oral anticoagu-
lants (NOACs) are increasingly being used. However,
there are no specific clinical trials or guidelines for AF
treatment in cancer patients (10). Post hoc analyses of
clinical trials such as the ROCKET AF (An Efficacy and
Safety Study of Rivaroxaban With Warfarin for the
Prevention of Stroke and Non–Central Nervous System
Systemic Embolism in Patients With Nonvalvular
Atrial Fibrillation; NCT00403767) and ARISTOTLE
(Apixaban for the Prevention of Stroke in SubjectsWith
Atrial Fibrillation; NCT00412984) trials have shown
that the relative efficacy and safety of NOACs do not
statistically differ from warfarin in patients with and
without a history of cancer for the prevention of
stroke/systemic embolism (SE) and the occurrence of
MB (11,12). There was, however, a greater benefit seen
in the composite of thrombotic events (stroke/SE,
myocardial infarction, and death) among apixaban
users with active cancer versus no cancer when
compared towarfarin users in the ARISTOTLE trial (12).
Real-world studies, though limited, have also
shown largely consistent results with the clinical tri-
als regarding the generally uniform benefits seen
among NOAC users regardless of cancer status (13-16).
Increased risk of cardiac complications, such as stroke
and MB, among AF patients with cancer (4-9)
necessitates a comprehensive evaluation of available
treatment strategies for this population. This sub-
group analysis of ARISTOPHANES (Anticoagulants for
Reduction In Stroke: Observational Pooled Analysis
on Health Outcomes and Experience of Patients;
NCT03087487), through the use of several data
sources, aimed to respectively compare the risk of
stroke/SE and MB among the nonvalvular AF (NVAF)
population with active cancer newly prescribed to
apixaban, dabigatran, rivaroxaban, or warfarin.
METHODS
DATA SOURCES AND PATIENT SELECTION. NVAF
patients with active cancer who were newly treated
with apixaban, dabigatran, rivaroxaban, edoxaban, or
warfarin were selected (17). Data were pooled from
the U.S. Centers for Medicare and Medicaid Services
(CMS) database and 4 U.S. commercial claims data-
bases: the IBM MarketScan Commercial Claims and
Encounter Database, the IQVIA PharMetrics Plus
Database, the Optum Clinformatics Data Mart, and
the Humana Research Database. Patients prescribed
edoxaban were not included in this study given an
insufficient sample size. Detailed data description
and pooling processes can be found in previously
published ARISTOPHANES reports (17,18).
From the ARISTOPHANES study population, NVAF
patients with active cancer were selected if they had
at least 1 OAC pharmacy claim from January 1, 2013, to
September 30, 2015 (identification period). Active
cancer was identified in patients who had at least 2
claims for cancer diagnosis or 1 claim for cancer
diagnosis plus at least 1 claim for cancer treatment
(eg, chemotherapy, radiation, cancer-related surgery)
within 6 months before OAC treatment initiation
(Supplemental Table 1). The first NOAC pharmacy
claim during the identification period was designated
as the index date for patients with any NOAC claim;
the first warfarin prescription date was designated as
the index date for those without a NOAC claim (19).
Patients were required to have an AF diagnosis before
or on the index date and needed continuous medical
and pharmacy health plan enrollment for $12 months
before the index date (baseline period). Patients were
not required to be newly diagnosed with AF or cancer,
but patients with OAC use during the baseline period
were excluded. Detailed exclusion criteria are listed
in Figure 1.
OUTCOME MEASURES. The primary outcomes were
time to first stroke/SE and time to first MB. Hospi-
talizations with stroke/SE or MB as the principal or
first-listed diagnosis were used as the primary
outcome measures. The primary effectiveness
ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial fibrillation
GI = gastrointestinal
GU = genitourinary
ICH = intracranial hemorrhage
MB = major bleeding
NOAC = non–vitamin K
antagonist oral anticoagulant
NVAF = nonvalvular atrial
fibrillation
PSM = propensity score
matching
SE = systemic embolism
VTE = venous
thromboembolism
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outcome of stroke/SE was further stratified by
ischemic stroke, hemorrhagic stroke, and SE. The
primary safety outcome of MB was further stratified
by gastrointestinal (GI) bleeding, intracranial hemor-
rhage (ICH), and MB in other key sites (17,20,21). Pa-
tients were followed from the day after the index date
to the earliest of 30 days after the date of discontin-
uation, switch, end of continuous medical and phar-
macy enrollment, death (all-cause deaths from
Medicare and hospitalization deaths from commercial
datasets), or end of study period (September 30,
2015). Discontinuation was defined as no evidence of
index OAC prescription for 30 days from the last day
of the last filled prescription days’ supply.
STATISTICAL ANALYSIS. All variables were stratified
by cohort and analyzed descriptively. Mean  SD
were provided for continuous variables. Frequencies
and percentages were provided for categoric vari-
ables. One-to-one propensity score matching (PSM)
was conducted in each database for all comparisons
before the datasets were pooled: NOAC versus
warfarin (apixaban vs warfarin, dabigatran vs
warfarin, and rivaroxaban vs warfarin) and NOAC
versus NOAC (apixaban vs dabigatran, apixaban vs
rivaroxaban, and dabigatran vs rivaroxaban) (17,18).
Propensity scores were generated by logistic regres-
sion with the use of the following variables: de-
mographics, Deyo-Charlson comorbidity index (CCI),
comorbidities, baseline medications, cancer metas-
tasis, and cancer-related treatment (variables are lis-
ted in Tables 1, 2, 3, and 4). Patients were matched by
nearest neighbor matching without replacement
(with a caliper of 0.01). The PSM-adjusted baseline
variables were compared based on standardized dif-
ferences, with a threshold of 10% for balance (22).
Kaplan-Meier curves were used to illustrate cu-
mulative incidence rates, and log-rank tests were
used to compare the curves across cohorts. Cox pro-
portional hazard models were used to evaluate the
risk of stroke/SE and MB with robust sandwich esti-
mates to account for correlation within the matched
populations (23). All matched confounders were
balanced after PSM; therefore, only OAC treatment
was included as an independent variable in the Cox
models. Hazard ratios (HRs) are expressed with 95%
confidence intervals (CIs). P values of <0.05 were
considered as statistically significant. Data analysis
was performed with the use of SAS statistical soft-
ware version 9.4 (SAS Institute).
SUBGROUP ANALYSIS. Subgroup analysis was con-
ducted for the following key cancer types across the
OAC cohorts: breast cancer, lung cancer, hematologic
cancer, genitourinary (GU) cancer, and upper/lower
GI cancer. Patients in the dabigatran cohort and those
with other cancer types were not included for the
subgroup analysis owing to limited sample size.
The PSM cohorts were stratified by the included
cancer type, and interactions between treatment
comparisons and cancer types on stroke/SE and
MB were evaluated. P values of <0.10 were
considered as statistically significant for the
interaction analysis.
ETHICAL APPROVAL. Because this study did not
involve the collection, use, or transmittal of individ-
ually identifiable data, it was exempt from institu-
tional review board review. Both the datasets and the
security of the offices where analysis was completed
(and where the datasets are kept) meet the re-
quirements of the Health Insurance Portability and
Accountability Act of 1996.
RESULTS
After applying the selection criteria, a total of 40,271
NVAF patients in the pooled datasets were identified
as also having active cancer, accounting for 9% of the
total ARISTOPHANES NVAF patient population
(N ¼ 466,991) (Figure 1). Among the NVAF patients
with active cancer, the index users of warfarin,
apixaban, dabigatran, and rivaroxaban numbered
15,371 (38%), 9,517 (24%), 2,742 (7%), and 12,641
(31%), respectively.
Before PSM, the majority of patients included in the
analysis had solid nonhematologic tumors (92%), with
prostate cancer being the most common cancer site
(29%), followed by female breast cancer (17%), GU
cancer (14%), lung cancer (13%), and GI cancer (13%).
More than one-half of the patients in each cohort re-
ported receiving a cancer-related treatment 6 months
before or on the index date (Supplemental Table 2).
Furthermore, the majority of apixaban, dabigatran,
and rivaroxaban users (73%, 81%, and 69%, respec-
tively) were on standard doses of each medication.
Before PSM, the incidence rates (per 100 person-years)
for sroke/SE and MB, respectively, were as follows:
warfarin: 2.64 and 10.56; apixaban: 1.45 and 6.01;
dabigatran: 1.92 and 5.38; and rivaroxaban: 1.72 and
8.01.
After 1:1 PSM, the following NOAC-warfarin com-
parison cohorts were formed: apixaban-warfarin with
8,236 pairs, dabigatran-warfarin with 2,470 pairs, and
rivaroxaban-warfarin with 9,988 pairs (Table 1 and 2).
The NOAC-NOAC comparison cohorts were formed as
apixaban-dabigatran with 2,413 pairs, apixaban-
rivaroxaban with 8,608 pairs, and dabigatran-
rivaroxaban with 2,553 pairs (Table 3 and 4). The
mean follow-up time for the 6 matched cohorts ranged
J A C C : C A R D I O O N C O L O G Y , V O L . 3 , N O . 3 , 2 0 2 1 Deitelzweig et al
S E P T E M B E R 2 0 2 1 : 4 1 1 – 4 2 4 OAC Use in NVAF Patients With Active Cancer
413
from 6 to 8 months. All baseline variables included in
the PSM logistic model were balanced with a stan-
dardized difference of <10%, resulting in well
balanced demographic and clinical characteristics be-
tween pairs. The Kaplan-Meier curves for cumulative
incidence rates of stroke/SE and MB in the matched
populations can be seen in Supplemental Figures 1 to
12.
NOAC-WARFARIN COMPARISONS. Among the NOAC
cohorts, apixaban patients had a lower risk for stroke/
TABLE 1 Post-PSM Baseline Characteristics of NOAC-Warfarin Cohorts
Apixaban vs Warfarin Dabigatran vs Warfarin Rivaroxaban vs Warfarin
Apixaban Warfarin Dabigatran Warfarin Rivaroxaban Warfarin
n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD
Sample size 8,236 100% 8,236 100% 2,470 100% 2,470 100% 9,988 100% 9,988 100%
Age, ya 78.00 7.60 77.90 7.51 76.67 7.41 76.78 7.61 77.41 7.45 77.40 7.55
18-54 24 0.29% 25 0.30% 12 0.49% 14 0.57% 24 0.24% 34 0.34%
55-64 174 2.11% 160 1.94% 67 2.71% 76 3.08% 258 2.58% 252 2.52%
65-74 2,617 31.78% 2,633 31.97% 905 36.64% 888 35.95% 3,358 33.62% 3,341 33.45%
$75 5,421 65.82% 5,418 65.78% 1,486 60.16% 1,492 60.40% 6,348 63.56% 6,361 63.69%
Sexa
Male 4,945 60.04% 4,961 60.24% 1,503 60.85% 1,523 61.66% 6,023 60.30% 6,016 60.23%
Female 3,291 39.96% 3,275 39.76% 967 39.15% 947 38.34% 3,965 39.70% 3,972 39.77%
U.S. geographic regiona
Northeast 1,636 19.86% 1,620 19.67% 541 21.90% 528 21.38% 2,093 20.96% 2,052 20.54%
Midwest 1,838 22.32% 1,865 22.64% 559 22.63% 593 24.01% 2,510 25.13% 2,536 25.39%
South 3,353 40.71% 3,331 40.44% 896 36.28% 872 35.30% 3,662 36.66% 3,684 36.88%
West 1,394 16.93% 1,406 17.07% 472 19.11% 476 19.27% 1,703 17.05% 1,697 16.99%
Other 15 0.18% 14 0.17% NR NR NR NR 20 0.20% 19 0.19%
Baseline comorbidity
Deyo-Charlson comorbidity indexa 4.64 3.56 4.62 3.55 4.12 3.42 4.08 3.35 4.61 3.55 4.62 3.58
CHA2DS2-VASc score 4.12 1.48 4.13 1.46 3.92 1.50 3.92 1.45 4.06 1.48 4.07 1.46
0 25 0.30% 21 0.25% 19 0.77% 13 0.53% 37 0.37% 48 0.48%
1 133 1.61% 138 1.68% 61 2.47% 58 2.35% 212 2.12% 196 1.96%
2 833 10.11% 750 9.11% 305 12.35% 290 11.74% 1,040 10.41% 945 9.46%
3 1,981 24.05% 2,019 24.51% 645 26.11% 656 26.56% 2,491 24.94% 2,460 24.63%
$4 5,264 63.91% 5,308 64.45% 1,440 58.30% 1,453 58.83% 6,208 62.15% 6,339 63.47%
HAS-BLED score 3.58 1.29 3.57 1.28 3.37 1.26 3.32 1.24 3.53 1.26 3.52 1.28
0 17.00 0.21% 15 0.18% 15 0.61% 10 0.40% 28 0.28% 31 0.31%
1 274 3.33% 281 3.41% 108 4.37% 114 4.62% 356 3.56% 361 3.61%
2 1,500 18.21% 1,507 18.30% 521 21.09% 547 22.15% 1,785 17.87% 1,883 18.85%
$3 6,445 78.25% 6,433 78.11% 1,826 73.93% 1,799 72.83% 7,819 78.28% 7,713 77.22%
Bleeding historya 2,889 35.08% 2,904 35.26% 812 32.87% 782 31.66% 3,569 35.73% 3,564 35.68%
Heart failurea 2,666 32.37% 2,661 32.31% 716 28.99% 729 29.51% 3,114 31.18% 3,123 31.27%
Diabetes mellitusa 3,129 37.99% 3,085 37.46% 938 37.98% 938 37.98% 3,894 38.99% 3,863 38.68%
Hypertensiona 7,514 91.23% 7,503 91.10% 2,197 88.95% 2,185 88.46% 9,068 90.79% 9,031 90.42%
Renal diseasea 2,656 32.25% 2,614 31.74% 567 22.96% 559 22.63% 2,881 28.84% 2,889 28.92%
Liver diseasea 799 9.70% 776 9.42% 207 8.38% 187 7.57% 1,062 10.63% 1,078 10.79%
Myocardial infarctiona 861 10.45% 898 10.90% 204 8.26% 222 8.99% 1,019 10.20% 1,047 10.48%
Dyspepsia or stomach discomforta 2,367 28.74% 2,340 28.41% 654 26.48% 637 25.79% 2,808 28.11% 2,807 28.10%
Non–stroke/SE peripheral vascular diseasea 4,952 60.13% 4,956 60.17% 1,408 57.00% 1,402 56.76% 5,914 59.21% 5,906 59.13%
Stroke/SEa 1,121 13.61% 1,158 14.06% 283 11.46% 298 12.06% 1,243 12.44% 1,277 12.79%
Transient ischemic attacka 673 8.17% 712 8.64% 183 7.41% 168 6.80% 766 7.67% 777 7.78%
Anemia and coagulation defectsa 3,680 44.68% 3,648 44.29% 997 40.36% 958 38.79% 4,358 43.63% 4,379 43.84%
Alcoholisma 179 2.17% 168 2.04% 60 2.43% 51 2.06% 229 2.29% 239 2.39%
Peripheral artery disease 2,121 25.75% 2,130 25.86% 597 24.17% 582 23.56% 2,505 25.08% 2,575 25.78%
Coronary artery disease 4,252 51.63% 4,295 52.15% 1,169 47.33% 1,205 48.79% 5,074 50.80% 5,046 50.52%
Dose of the index prescription
Standard doseb 5,920 71.88% NA NA 1,973 79.88% NA NA 6,619 66.27% NA NA
Low dosec 2,316 28.12% NA NA 497 20.12% NA NA 3,369 33.73% NA NA
Continued on the next page
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SE compared with those prescribed warfarin (HR:
0.59; 95% CI: 0.45-0.78) (Central Illustration). Dabi-
gatran and rivaroxaban patients had a similar risk for
stroke/SE compared with warfarin patients (dabiga-
tran: HR: 0.88 [95% CI: 0.54-1.41]; rivaroxaban: HR:
0.82 [95% CI: 0.62-1.08]). Ischemic stroke was the
most common embolic event, with a lower risk in
apixaban patients (HR: 0.72; 95% CI: 0.52-0.99) and
similar risks in dabigatran (HR: 0.95; 95% CI: 0.54-
1.66) and rivaroxaban (HR: 1.02; 95% CI: 0.76-1.37)
patients compared with warfarin patients.
The apixaban cohort was the only cohort that had a
significantly lower risk for MB compared with the
warfarin cohort (HR: 0.58; 95% CI: 0.50-0.68). Dabi-
gatran and rivaroxaban patients had a similar risk of
MB compared with warfarin patients (dabigatran: HR:
0.76 [95% CI: 0.57-1.01]; rivaroxaban: HR: 0.95 [95%
CI: 0.85-1.06]).
Apixaban patients experienced a lower risk for all 3
types of MB compared with warfarin patients. Dabi-
gatran patients had a lower risk for other MB
compared with warfarin patients (HR: 0.65; 95% CI:
0.44-0.95), and rivaroxaban patients had a reduced
risk for ICH compared with warfarin patients (HR:
0.49; 95% CI: 0.35-0.69).
NOAC-NOAC COMPARISONS. Apixaban patients had
a lower risk for stroke/SE compared with dabigatran
patients (HR: 0.41; 95% CI: 0.22-0.77) (Figure 2).
Similar risks for stroke/SE were seen in the apixaban-
rivaroxaban comparison (HR: 0.81; 95% CI: 0.60-1.08)
and the dabigatran-rivaroxaban comparison (HR:
0.90; 95% CI: 0.50-1.63).
When evaluating MB, apixaban patients had a
lower risk compared with rivaroxaban patients
(HR: 0.66; 95% CI: 0.54-0.80) and a similar risk
compared with dabigatran patients (HR: 0.83; 95% CI:
0.58-1.19). Dabigatran patients also experienced a
lower risk for MB compared with those prescribed
rivaroxaban (HR: 0.71; 95% CI: 0.52-0.95). The apix-
aban cohort continued to show a lower risk for MB
compared with the rivaroxaban cohort in terms of GI
bleeding (HR: 0.56; 95% CI: 0.45-0.69) and bleeding
in other major sites (HR: 0.70; 95% CI: 0.54-0.91). The
other NOAC-NOAC comparisons for the MB compo-
nents all yielded similar risks to one another.
SUBGROUP ANALYSIS. No significant interactions
were seen between treatment comparisons and the
included cancer types for stroke/SE and MB. Treat-
ment effects were consistent across different cancer
types (Figures 3 and 4). Owing to the small sample size
of patients with the included cancer types, the sub-
group analysis was not evaluated for the dabiga-
tran cohorts.
DISCUSSION
As far as we are aware, this is the largest contempo-
rary cohort of NVAF patients with active cancer
treated with NOACs and warfarin. Our principal
findings in this subgroup analysis of the ARISTO-
PHANES study of NVAF patients with active cancer
are that compared with warfarin, apixaban was
associated with a lower risk of stroke/SE and MB and
dabigatran and rivaroxaban had similar risks of
stroke/SE and MB. Second, risks of stroke/SE and MB
varied among NOAC-NOAC comparisons: apixaban
patients had a lower risk of stroke/SE compared with
dabigatran users, and a lower risk of MB compared
with rivaroxaban users; and dabigatran patients
experienced a lower risk in MB compared with those
prescribed rivaroxaban. Third, when evaluating
TABLE 1 Continued
Apixaban vs Warfarin Dabigatran vs Warfarin Rivaroxaban vs Warfarin
Apixaban Warfarin Dabigatran Warfarin Rivaroxaban Warfarin
n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD
Follow-up time, days 181.10 165.61 228.54 214.08 222.27 223.36 229.25 214.07 214.88 207.85 227.94 212.57
Median 120 145 121 147 129 145
Reasons for censoring
Discontinuation 3,183 38.65% 4,835 58.71% 1,442 58.38% 1,460 59.11% 5,206 52.12% 5,952 59.59%
Switch 320 3.89% NA NA 269 10.89% NA NA 677 6.78% NA NA
Death 461 5.60% 801 9.73% 160 6.48% 208 8.42% 711 7.12% 962 9.63%
End of continuous medical/pharmacy enrollment 98 1.19% 168 2.04% 40 1.62% 61 2.47% 230 2.30% 222 2.22%
End of study period 4,174 50.68% 2,432 29.53% 559 22.63% 741 30.00% 3,164 31.68% 2,852 28.55%
Cells with n < 11 are not reported (NR). aVariable used in propensity score matching. b5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. c2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban;
560 and 2,809 patients received 10 mg and 15 mg rivaroxaban, respectively, in the rivaroxaban-warfarin matched cohort.
CHA2DS2-Vasc ¼ congestive heart failure, hypertension, age $ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category; HAS-BLED ¼
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; NA ¼ not applicable; NOAC ¼ non–vitamin K antagonist oral
anticoagulant; PSM ¼ propensity score matching; SD ¼ standard deviation; SE ¼ systemic embolism.
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patients according to major cancer types, consistent
treatment effects on stroke/SE or MB were seen for
the NOAC-warfarin and NOAC-NOAC comparisons
across the different cancer types. As an ad hoc anal-
ysis of the ARISTOPHANES study focusing on patients
with active cancer, the results of this analysis were
generally consistent with the findings of the main
ARISTOPHANES analysis on the whole patient popu-
lation regardless of active cancer status (17). Both
analyses showed that NOACs were associated with
better or similar safety and effectiveness compared
with warfarin. In addition, the present analysis
showed consistent treatment effects across key can-
cer types.
Active cancer patients are more susceptible to
developing not only cardiac disturbances such as
NVAF, but also other thromboembolic and bleeding
complications, such as ischemic stroke and MB,
FIGURE 1 Selection Criteria
The inclusion and exclusion criteria of this study yielded over 466,000 patients with nonvalvular atrial fibrillation, of which 40,271 had active
cancer. These patients were matched into NOAC-warfarin and NOAC-NOAC cohorts via propensity score matching. AF ¼ atrial fibrillation;
CMS ¼ U.S. Centers for Medicare and Medicaid Services; ICD-9/10-CM ¼ International Classification of Diseases-9th/-10th Revision, Clinical
Modification; NOAC ¼ non–vitamin K antagonist oral anticoagulant; OAC ¼ oral anticoagulant; PSM ¼ propensity score matching;
VTE ¼ venous thromboembolism.
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compared with noncancer individuals (4-9). Owing to
these increased risks, this patient population poses a
unique challenge regarding anticoagulation manage-
ment (24). However, current AF guidelines for cancer
patients have yet to strongly recommend any specific
treatment owing to the lack of evidence and research
conducted within this at-risk patient population
(25,26). This underscores the urgency in evaluating
the potential risks and benefits of available treatment
strategies for NVAF active cancer patients.
A recent systematic review and meta-analysis of
post hoc analyses from the ROCKET AF, ENGAGE AF–
TIMI 48 (Effective Anticoagulation with Factor Xa
Next Generation in Atrial Fibrillation-Thrombolysis In
Myocardial Infarction 48), and ARISTOTLE trials, and
2 other cohort studies that compared NOACs with
warfarin among AF patients with cancer showed re-
sults similar to those found in our analysis (25). The
meta-analysis found that NOAC use was significantly
associated with a reduced risk of stroke/SE (risk ratio
[RR]: 0.52; 95% CI: 0.28-0.99) and a decreased risk of
intracranial or GI bleeding (RR: 0.65; 95% CI: 0.42-
0.98). In addition, NOAC use had a tendency toward
significantly reducing the risk of MB (RR: 0.73; 95%
CI: 0.53-1.00) in NVAF cancer patients.
Real-world studies that have investigated the
impact of NOAC treatments in NVAF patients with
active cancer are limited (13-16). In a Korean retro-
spective study, NVAF active cancer patients using
NOACs (apixaban, dabigatran, and rivaroxaban)
experienced lower stroke/SE, MB, and all-cause
death incidence rates than those in the PSM
warfarin cohort (13). A U.S. study using the Market-
Scan claims database identified 16,096 AF patients
who were actively treated for cancer during the time
of anticoagulation initiation (15). In that MarketScan
study, patients initiating apixaban had significantly
lower rates of severe bleeding (HR: 0.37; 95% CI:
TABLE 2 Post-PSM Cancer-Related Baseline Characteristics of NOAC-Warfarin Cohorts
Apixaban vs Warfarin Dabigatran vs Warfarin Rivaroxaban vs Warfarin
Apixaban Warfarin Dabigatran Warfarin Rivaroxaban Warfarin
n % n % n % n % n % n %
Sample size 8,236 100 8,236 100 2,470 100 2,470 100 9,988 100 9,988 100
Cancer site
Prostate 2,483 30.15 2,343 28.45 745 30.16 740 29.96 2,938 29.42 2,780 27.83
Female breast 1,497 18.18 1,398 16.97 468 18.95 430 17.41 1,757 17.59 1,704 17.06
Gastrointestinal(GI)a 1,004 12.19 1,100 13.36 288 11.66 312 12.63 1,338 13.40 1,403 14.05
Lung 946 11.49 1,156 14.04 269 10.89 357 14.45 1,228 12.29 1,448 14.50
Lymphoma 935 11.35 895 10.87 285 11.54 266 10.77 1,160 11.61 1,094 10.95
Lower GIb 751 9.12 792 9.62 200 8.10 219 8.87 972 9.73 1,000 10.01
Bladder 669 8.12 703 8.54 204 8.26 171 6.92 789 7.90 792 7.93
Leukemia 479 5.82 480 5.83 144 5.83 132 5.34 559 5.60 561 5.62
Renal cell carcinoma 368 4.47 386 4.69 90 3.64 99 4.01 408 4.08 453 4.54
Gynecologicc 256 3.11 255 3.10 80 3.24 79 3.20 350 3.50 326 3.26
Multiple myeloma 217 2.63 250 3.04 71 2.87 69 2.79 285 2.85 295 2.95
Upper GId 133 1.61 169 2.05 37 1.50 52 2.11 193 1.93 209 2.09
Pancreas 79 0.96 106 1.29 31 1.26 31 1.26 120 1.20 128 1.28
Stomach 66 0.80 98 1.19 24 0.97 33 1.34 96 0.96 130 1.30
Brain tumor 67 0.81 73 0.89 28 1.13 20 0.81 87 0.87 96 0.96
Testicular 11 0.13 NR NR NR NR NR NR 24 0.24 11 0.11
Cancer metastasise 1,231 14.95 1,237 15.02 308 12.47 306 12.39 1,612 16.14 1,601 16.03
Cancer type
Hematologic 1,328 16.12 1,293 15.70 400 16.19 379 15.34 1,591 15.93 1,567 15.69
Nonhematologic 7,621 92.53 7,618 92.50 2,260 91.50 2,284 92.47 9,257 92.68 9,221 92.32
Cancer-related treatment 4,458 54.13 4,399 53.41 1,258 50.93 1,239 50.16 5,411 54.18 5,423 54.30
Chemotherapye 3,793 46.05 3,753 45.57 1,033 41.82 1,018 41.21 4,583 45.89 4,572 45.77
Hormone therapye 593 7.20 565 6.86 189 7.65 191 7.73 722 7.23 716 7.17
Radiatione 708 8.60 697 8.46 217 8.79 214 8.66 936 9.37 922 9.23
Cancer-related surgerye 245 2.97 224 2.72 66 2.67 63 2.55 323 3.23 313 3.13
Cells with n < 11 are not reported (NR). Immunotherapy was also assessed as a cancer-related treatment but had too few patients to report (n < 11). aGI cancer includes
esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum, and anus cancers. bLower GI cancer includes small intestine, large intestine, rectum, and
anus cancers. cGynecologic cancer includes uterus, cervix, placenta, ovary, and other female genital organ cancers. dUpper GI cancer includes esophagus and stomach cancers.
eVariable used in propensity score matching.
Abbreviations as in Table 1.
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0.17-0.79) and had similar rates of ischemic stroke
and other bleeding compared with warfarin users.
Dabigatran and rivaroxaban had similar rates of
ischemic stroke and severe bleeding compared with
warfarin users. These MarketScan results are
generally consistent with those of our study; how-
ever, our analysis included significantly more pa-
tients and additional comparisons.
STUDY LIMITATIONS. To the best of our knowledge,
this study represents the largest cohort of NVAF
TABLE 3 Post-PSM Baseline Characteristics of NOAC-NOAC Cohorts
Apixaban vs Dabigatran Apixaban vs Rivaroxaban Dabigatran vs Rivaroxaban
Apixaban Dabigatran Apixaban Rivaroxaban Dabigatran Rivaroxaban
n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD
Sample size 2,413 100% 2,413 100% 8,608 100% 8,608 100% 2,553 100% 2,553 100%
Age, ya 76.95 7.51 76.58 7.49 77.43 7.80 77.39 7.68 76.13 7.73 76.17 7.70
18-54 NR NR NR NR 47 0.55% 42 0.49% 11 0.43% 19 0.74%
55-64 71 2.94% 71 2.94% 273 3.17% 258 3.00% 125 4.90% 114 4.47%
65-74 893 37.01% 897 37.17% 2,840 32.99% 2,836 32.95% 947 37.09% 957 37.49%
$75 1,442 59.76% 1,435 59.47% 5,448 63.29% 5,472 63.57% 1,470 57.58% 1,463 57.31%
Sexa
Male 1,498 62.08% 1,457 60.38% 5,209 60.51% 5,191 60.30% 1,558 61.03% 1,581 61.93%
Female 915 37.92% 956 39.62% 3,399 39.49% 3,417 39.70% 995 38.97% 972 38.07%
U.S. geographic regiona
Northeast 513 21.26% 514 21.30% 1,629 18.92% 1,671 19.41% 549 21.50% 550 21.54%
Midwest 518 21.47% 539 22.34% 1,817 21.11% 1,825 21.20% 576 22.56% 600 23.50%
South 932 38.62% 927 38.42% 3,756 43.63% 3,733 43.37% 958 37.52% 960 37.60%
West 449 18.61% 431 17.86% 1,390 16.15% 1,365 15.86% 467 18.29% 441 17.27%
Other NR NR NR NR 16 0.19% 14 0.16% NR NR NR NR
Baseline comorbidity
Deyo-Charlson comorbidity indexa 4.06 3.40 4.00 3.38 4.42 3.53 4.42 3.52 3.94 3.37 3.99 3.27
CHA2DS2-VASc score 3.90 1.47 3.91 1.50 4.02 1.49 4.02 1.51 3.83 1.53 3.84 1.51
0 11 0.46% 13 0.54% 42 0.49% 53 0.62% 29 1.14% 18 0.71%
1 63 2.61% 67 2.78% 188 2.18% 205 2.38% 85 3.33% 93 3.64%
2 294 12.18% 305 12.64% 974 11.32% 961 11.16% 344 13.47% 356 13.94%
3 650 26.94% 639 26.48% 2,127 24.71% 2,139 24.85% 672 26.32% 642 25.15%
$4 1,395 57.81% 1,389 57.56% 5,277 61.30% 5,250 60.99% 1,423 55.74% 1,444 56.56%
HAS-BLED score 3.40 1.26 3.38 1.26 3.50 1.28 3.50 1.27 3.32 1.29 3.31 1.25
0 9 0.37% 15 0.62% 26 0.30% 33 0.38% 23 0.90% 12 0.47%
1 101 4.19% 103 4.27% 348 4.04% 349 4.05% 138 5.41% 133 5.21%
2 508 21.05% 505 20.93% 1,646 19.12% 1,559 18.11% 552 21.62% 556 21.78%
$3 1,795 74.39% 1,790 74.18% 6,588 76.53% 6,667 77.45% 1,840 72.07% 1,852 72.54%
Bleeding historya 782 32.41% 780 32.32% 2,878 33.43% 2,844 33.04% 811 31.77% 780 30.55%
Heart failurea 698 28.93% 696 28.84% 2,613 30.36% 2,609 30.31% 712 27.89% 722 28.28%
Diabetes mellitusa 893 37.01% 893 37.01% 3,145 36.54% 3,169 36.81% 933 36.55% 957 37.49%
Hypertensiona 2,152 89.18% 2,153 89.23% 7,813 90.76% 7,805 90.67% 2,262 88.60% 2,277 89.19%
Renal diseasea 555 23.00% 542 22.46% 2,455 28.52% 2,449 28.45% 551 21.58% 563 22.05%
Liver diseasea 225 9.32% 199 8.25% 803 9.33% 800 9.29% 205 8.03% 190 7.44%
Myocardial infarctiona 219 9.08% 199 8.25% 838 9.74% 852 9.90% 202 7.91% 213 8.34%
Dyspepsia or stomach discomforta 658 27.27% 636 26.36% 2,402 27.90% 2,410 28.00% 653 25.58% 665 26.05%
Non–stroke/SE peripheral vascular diseasea 1,342 55.62% 1,363 56.49% 5,081 59.03% 5,109 59.35% 1,421 55.66% 1,429 55.97%
Stroke/SEa 270 11.19% 272 11.27% 1,087 12.63% 1,088 12.64% 281 11.01% 282 11.05%
Transient ischemic attacka 159 6.59% 179 7.42% 714 8.29% 703 8.17% 186 7.29% 179 7.01%
Anemia and coagulation defectsa 972 40.28% 965 39.99% 3,602 41.84% 3,631 42.18% 1,001 39.21% 967 37.88%
Alcoholisma 63 2.61% 57 2.36% 180 2.09% 172 2.00% 66 2.59% 68 2.66%
Peripheral artery disease 552 22.88% 580 24.04% 2,130 24.74% 2,145 24.92% 604 23.66% 609 23.85%
Coronary artery disease 1,160 48.07% 1,139 47.20% 4,355 50.59% 4,396 51.07% 1,179 46.18% 1,209 47.36%
Dose of the index prescription
Standard doseb 1,862 77.17% 1,940 80.40% 6,346 73.72% 5,728 66.54% 2,058 80.61% 1,793 70.23%
Low dosec 551 22.83% 473 19.60% 2,262 26.28% 2,880 33.46% 495 19.39% 760 29.77%
Continued on the next page
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TABLE 3 Continued
Apixaban vs Dabigatran Apixaban vs Rivaroxaban Dabigatran vs Rivaroxaban
Apixaban Dabigatran Apixaban Rivaroxaban Dabigatran Rivaroxaban
n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD
Follow-up time, days 186.88 169.89 224.31 224.61 182.10 166.01 217.29 209.18 224.44 225.79 220.97 210.09
Median 122 122 121 132 120 139
Reasons for censoring
Discontinuation 930 38.54% 1,407 58.31% 3,344 38.85% 4,531 52.64% 1,495 58.56% 1,327 51.98%
Switch 87 3.61% 255 10.57% 337 3.91% 557 6.47% 274 10.73% 197 7.72%
Death 96 3.98% 158 6.55% 453 5.26% 599 6.96% 157 6.15% 137 5.37%
End of continuous medical/pharmacy enrollment 27 1.12% 35 1.45% 125 1.45% 201 2.34% 49 1.92% 69 2.70%
End of study period 1,273 52.76% 558 23.12% 4,349 50.52% 2,720 31.60% 578 22.64% 823 32.24%
Cells with n< 11 are not reported (NR). aVariable used in propensity score matching. b5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. c2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban. 507
and 2,373 patients received 10 mg and 15 mg rivaroxaban, respectively, in the apixaban-rivaroxaban matched cohort and 133 and 627 patients received 10 mg and 15 mg rivaroxaban, respectively, in the
dabigatran-rivaroxaban matched cohort.
Abbreviations as in Table 1.
TABLE 4 Post-PSM Cancer Related Baseline Characteristics of NOAC-NOAC Cohorts
Apixaban vs Dabigatran Apixaban vs Rivaroxaban Dabigatran vs Rivaroxaban
Apixaban Dabigatran Apixaban Rivaroxaban Dabigatran Rivaroxaban
n % n % n % n % n % n %
Sample size 2,413 100 2,413 100 8,608 100 8,608 100 2,553 100 2,553 100
Cancer site
Prostate 762 31.58 738 30.58 2,650 30.79 2,573 29.89 782 30.63 760 29.77
Female breast 446 18.48 467 19.35 1,593 18.51 1,536 17.84 485 19.00 451 17.67
Gastrointestinal(GI)a 286 11.85 286 11.85 1,015 11.79 1,120 13.01 300 11.75 280 10.97
Lung 268 11.11 263 10.90 962 11.18 997 11.58 282 11.05 298 11.67
Lymphoma 276 11.44 253 10.48 991 11.51 1,032 11.99 267 10.46 320 12.53
Lower GIb 218 9.03 204 8.45 756 8.78 830 9.64 214 8.38 215 8.42
Bladder 188 7.79 194 8.04 671 7.80 682 7.92 210 8.23 193 7.56
Leukemia 139 5.76 138 5.72 480 5.58 466 5.41 145 5.68 170 6.66
Renal cell carcinoma 98 4.06 89 3.69 372 4.32 341 3.96 89 3.49 108 4.23
Gynecologicc 75 3.11 79 3.27 265 3.08 289 3.36 81 3.17 73 2.86
Multiple myeloma 57 2.36 67 2.78 218 2.53 238 2.76 69 2.70 71 2.78
Upper GId 40 1.66 34 1.41 140 1.63 178 2.07 36 1.41 23 0.90
Pancreas 19 0.79 29 1.20 82 0.95 88 1.02 31 1.21 32 1.25
Stomach 15 0.62 28 1.16 68 0.79 70 0.81 30 1.18 19 0.74
Brain tumor 18 0.75 22 0.91 72 0.84 89 1.03 23 0.90 13 0.51
Testicular NR NR NR NR 14 0.16 19 0.22 NR NR NR NR
Cancer metastasise 296 12.27 283 11.73 1,242 14.43 1,233 14.32 297 11.63 299 11.71
Cancer type
Hematologic 384 15.91 373 15.46 1,357 15.76 1,363 15.83 399 15.63 431 16.88
Nonhematologic 2,243 92.95 2,222 92.08 7,975 92.65 7,971 92.60 2,341 91.70 2,334 91.42
Cancer-related treatment 1,228 50.89 1,230 50.97 4,608 53.53 4,629 53.78 1,297 50.80 1,294 50.69
Chemotherapye 1,017 42.15 1,003 41.57 3,883 45.11 3,896 45.26 1,052 41.21 1,049 41.09
Hormone therapye 165 6.84 187 7.75 656 7.62 641 7.45 195 7.64 183 7.17
Radiatione 231 9.57 213 8.83 762 8.85 764 8.88 238 9.32 255 9.99
Cancer-related surgerye 66 2.74 70 2.90 257 2.99 265 3.08 68 2.66 77 3.02
Cells with n < 11 are not reported (NR). Immunotherapy was also assessed as a cancer-related treatment but had too few patients to report (n < 11). aGI cancer includes esophagus, stomach, biliary system,
pancreas, small intestine, large intestine, rectum, and anus cancers. bLower GI cancer includes small intestine, large intestine, rectum, and anus cancers. cGynecologic cancer includes uterus, cervix, placenta,
ovary, and other female genital organ cancers. dUpper GI cancer includes esophagus and stomach cancers. eVariable used in propensity score matching.
Abbreviations as in Table 1.
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CENTRAL ILLUSTRATION NOAC Versus Warfarin: PSM Incidence Rates and Hazard Ratios of
Stroke/SE and MB
Deitelzweig, S. et al. J Am Coll Cardiol CardioOnc. 2021;3(3):411–424.
Incidence rates [IR] (per 100 person-years) and hazard ratios (with 95% confidence intervals [CIs]) of non–vitamin K oral anticoagulants
(NOACs) vs warfarin. Apixaban was associated with a lower risk for stroke/systemic embolism (SE) and major bleeding (MB) compared with
warfarin, and dabigatran and rivaroxaban were associated with similar risks for stroke/SE and MB compared with warfarin. Risk of SE is not
reported for dabigatran versus warfarin comparison owing to small sample size. *P value is considered to be significant because the upper
limit of the 95% CI was rounded from 0.997 to 1.00. GI ¼ gastrointestinal; ICH ¼ intracranial hemorrhage.
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active cancer patients who have been treated with
NOACs and warfarin. Using a pooled analysis of 5
U.S. claims databases, this study provides a signifi-
cant sample size and sufficient statistical power. As
a retrospective observational study, however,
several limitations need to be noted for
this analysis.
First, the results of this study can only be repre-
sentative of statistical associations, not causal re-
lationships, between the exposures of interest and
study outcomes. Even with the use of PSM, the
matched cohorts are subject to residual
confounders, such as over-the-counter aspirin use or
lack of laboratory values, which is especially impor-
tant when interpreting NOAC-NOAC comparisons.
These comparisons are primarily intended for hy-
pothesis generation, given the lack of head-to-head
clinical trials.
Second, claims database studies used only ICD-9-
CM, CPT, and HCPCS codes to identify outcomes and
clinical conditions. These codes lack crucial clinical
information on pathology, and are prone to misclas-
sification, which has been observed in cancer metas-
tasis diagnosis (27,28). For example, detailed
characteristics including cancer stage, progression,
and primary versus secondary cancer diagnosis are
lacking in our analysis, which may be pivotal in un-
derstanding potential variations in NVAF treatment
outcomes as a result of severity of cancer status and/or
type. The evaluation of label-adherent dosing for
apixaban is also deterred because information on pa-
tient weight and renal function, which are needed to
assess whether apixaban dose has been used appro-
priately or not, are not available in the claims data used
in this study. Furthermore, because of the study period
of this analysis, cancer treatment advancements that
FIGURE 2 NOAC Versus NOAC: PSM Incidence Rates and Hazard Ratios of Stroke/SE and MB
Incidence rates (IRs) (per 100 person-years) and hazard ratios (HRs) (with 95% confidence intervals [CIs]) of NOACs vs NOACs. Apixaban was associated with a lower
risk of stroke/SE compared with dabigatran users, and a lower risk of MB compared with rivaroxaban. Dabigatran was associated with a lower risk in MB compared with
rivaroxaban. Risk of SE is not reported for apixaban vs dabigatran comparisons owing to small sample size. *Upper limit of 95% CI extends beyond chart.
GI ¼ gastrointestinal; ICH ¼ intracranial hemorrhage; MB ¼ major bleeding; SE ¼ systemic embolism; other abbreviations as in Figure 1.
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have led to improvements in major health outcomes
(eg, MB in hematologic cancers) also are not consid-
ered. In addition, this analysis had a relatively short
mean follow-up time of 6-8 months.
It should also be noted that unobserved heteroge-
neity may exist across the 5 datasets used in this
analysis. The likelihood of duplicate observations is
relatively low, researched to be 0.5%, and is not likely
to have a significant impact on study results (29).
Although this study represents the largest-to-date
real-world retrospective claims study of NOAC
versus warfarin and NOAC versus NOAC comparisons
among active cancer patients with NVAF, it is not
reflective of the overall active cancer NVAF popula-
tion in the US. Uninsured patients and patients
solely covered by other public health insurance plans
were not included in this analysis. More studies are
needed to better understand the effectiveness and
safety of OACs in specific cancer populations. Owing
to limited sample size, especially for dabigatran pa-
tients, dose was not assessed in separate subgroup
analyses. In addition, future analyses with increased
sample sizes of dabigatran patients would allow more
confidence in the present findings for this patient
cohort (large confidence intervals in the risk esti-
mates for dabigatran vs other OACs were observed
because of small sample size).
CONCLUSIONS
Among NVAF patients with active cancer, apixaban
was associated with a lower risk, and dabigatran and
rivaroxaban with similar risks of stroke/SE and MB
compared with warfarin. Apixaban users also had a
FIGURE 3 PSM HRs of Stroke/SE for Cancer Subgroups
HRs (95% CIs) of stroke/SE for NOACs vs warfarin and NOACs vs NOACs within cancer subgroups. P value represents statistically significant interaction between
treatment and cancer type. No significant interactions were observed; treatment effect was consistent across cancer types. GU ¼ genitourinary; other abbreviations as
in Figures 1 and 2.
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lower risk of stroke/SE comparedwith dabigatran users
and a lower risk of MB compared with rivaroxaban
users. Dabigatran was associated with a lower risk of
MB compared with rivaroxaban. Treatment effects
were consistent across several common cancer types
for NOAC-warfarin and NOAC-NOAC comparisons.
Subsequent real-world studies are warranted to
further study the impact of NOAC treatment options in
the NVAF cancer population, specifically addressing
NOAC treatment outcomes within specific cancer
subtypes.
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FIGURE 4 PSM HRs of Major Bleeding for Cancer Subgroups
HRs (95% CIs) of MB for NOACs vs warfarin and NOACs vs NOACs within cancer subgroups. P value represents statistically significant interaction between treatment
and cancer type. No significant interactions were observed; treatment effect was consistent across cancer types. Abbreviations as in Figures 1 to 3.
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figures, please see the online version of this
paper.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In NVAF
patients with active cancer, initiation of NOACs is asso-
ciated with a similar or reduced risk in thromboembolic
and bleeding complications compared with treatment
with warfarin. These findings were consistent across
several common cancer types.
TRANSLATIONALOUTLOOK: Future studies are needed
to further understand patient- and dosing-specific charac-
teristics to enhance the safety and effectiveness of NOACs in
the cancer population. A more detailed evaluation of NOAC
treatment outcomes according to specific cancer types and
disease severity is necessary.
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